Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer

被引:66
|
作者
Aletti, Giovanni D. [1 ]
Dowdy, Sean [1 ]
Podratz, Karl C. [1 ]
Cliby, William A. [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Dept Obstet & Gynecol, Rochester, MN 55905 USA
关键词
lymphadenectomy; cytoreduction; node metastasis; ovarian cancer;
D O I
10.1016/j.ajog.2006.06.068
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to determine the factors that are related to the performance of lymph node assessment and its impact on prognosis in ovarian cancer. Study design: This was a retrospective analysis of stage IIIC/IV epithelial ovarian cancer in patients who had undergone primary surgery between 1994 and 1998. Simple statistics and univariate and multivariable analysis were performed. Results: Two hundred nineteen patients met the inclusion criteria; lymph node assessment was performed for 93 of these patients (41%). Sixty-one patients (65.5%) underwent complete pelvic and para-aortic lymphadenectomy, and 32 patients (34.5%) underwent a more limited lymph node sampling. In patients with residual disease > 1 cm, lymph node assessment was an independent predictor of outcome. In this same subgroup, lymphadenectomy appeared to be superior to lymph node sampling (5-year overall survival, 50% (lymphadenectomy) vs 33% (lymph node sampling) vs 29% (no lymph node assessment); P =.01). Considering survival of the subgroup who underwent lymph node assessment, we observed a significantly worse outcome for those with lymphatic involvement (5-year overall survival, 31.5% [positive for nodal metastases] vs 54% [negative for nodal metastases]; P =.003). Although multiple factors were correlated with the decision to perform lymph node assessment in univariate analysis, only the surgeon (P <.001), low residual disease (P =.004), American Society of Anesthesiology I or 2 (P =.004), and the absence of carcinomatosis (P =.0002) were independent factors in the multivariable analysis. Further, if lymph node assessment was performed, the decision to do lymphadenectomy versus lymph node sampling was associated independently with the surgeon (P <.001), low residual disease (P <.001), and patient age of < 65 years (P <.001). Conclusion: Removal of obviously involved lymph nodes in patients with residual disease near 1 cm and lymphadenectomy for patients with complete or near complete resection of abdominal disease appears to be justified. A lack of standard recommendation in advanced ovarian cancer results in wide variations that are based on individual preference in addition to logical factors. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:1862 / 1868
页数:7
相关论文
共 50 条
  • [21] The insolvable problem; survival effect of lymphadenectomy in advanced stage ovarian cancer
    Bakir, Mehmet Sait
    Birge, Ozer
    Karadag, Ceyda
    Dogan, Selen
    Tuncer, Hasan Aykut
    Simsek, Tayup
    [J]. GINEKOLOGIA POLSKA, 2021, 92 (12) : 829 - 836
  • [22] Role of obesity in the surgical management of advanced-stage ovarian cancer
    Wolfberg, AJ
    Montz, FJ
    Bristow, RE
    [J]. JOURNAL OF REPRODUCTIVE MEDICINE, 2004, 49 (06) : 473 - 476
  • [23] ASSESSMENT ON THE ROLE OF SYSTEMATIC LYMPHADENECTOMY IN PATIENTS WITH ADVANCED OVARIAN CANCER
    Inaba, H.
    Eguchi, S.
    Kashiyama, T.
    Miyamoto, Y.
    Tanikawa, M.
    Sone, K.
    Mori, M.
    Tsuruga, T.
    Nagasaka, K.
    Matsumoto, Y.
    Oda, K.
    Osuga, Y.
    Fujii, T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 708 - 708
  • [24] Neoadjuvant chemotherapy in advanced stage epithelial ovarian cancer
    Kartsiounis, Christos
    Mitsakis, Ioannis
    Boutis, Anastasios
    Triantafillidis, Efstathios
    Evangelinos, Dimitrios
    Andreadis, Charalambos
    Kellartzis, Argirios
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 175 - 175
  • [25] The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer
    Kroep, Judith R.
    Nortier, Johan W. R.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (25) : 3775 - 3783
  • [26] The role of surgery in advanced epithelial ovarian cancer
    Martin-Camean, Maria
    Delgado-Sanchez, Elsa
    Pinera, Antonio
    Dolores Diestro, Maria
    De Santiago, Javier
    Zapardiel, Ignacio
    [J]. ECANCERMEDICALSCIENCE, 2016, 10
  • [27] MANAGEMENT OF APPARENT SINGLE FOCI OF EPITHELIAL OVARIAN-CANCER
    BRUCKNER, HW
    GORBATY, M
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1987, 35 (03) : 204 - 206
  • [28] Real-world study of lymphadenectomy in patients with advanced epithelial ovarian cancer
    Yin, Ziran
    Wang, Ming
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (04) : 663 - 670
  • [29] Systematic lymphadenectomy in advanced epithelial ovarian cancer: Two decades of uncertainty resolved
    Chambers, SK
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (08) : 548 - 549
  • [30] Role of lymphadenectomy for ovarian cancer
    Mikami, Mikio
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2014, 25 (04) : 279 - 281